This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

High Dose Cyclophosphamide for Treatment of Scleroderma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Fredrick M. Wigley, Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT00501995
First received: July 13, 2007
Last updated: May 15, 2017
Last verified: May 2017
Results First Received: March 25, 2014  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Scleroderma
Intervention: Drug: IV Cyclophosphamide

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
IV Cyclophosphamide (50 mg/kg)

This is an open-labeled single arm study of Cyclophosphamide (50 mg/kg) administered intravenously over 1 hour daily for four consecutive days (200 mg/kg total) through a Hickman catheter .

IV Cyclophosphamide: Cyclophosphamide (50 mg/kg) intravenously daily for 4 consecutive days (total 200 mg/kg) followed by granulocyte colony-stimulating factor (5 µg/kg/day)


Participant Flow:   Overall Study
    IV Cyclophosphamide (50 mg/kg)
STARTED   6 
COMPLETED   5 
NOT COMPLETED   1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Patients with scleroderma were considered eligible for this open-label trial if they had a diagnosis of diffuse cutaneous scleroderma and evidence of clinically active disease.

Reporting Groups
  Description
IV Cyclophosphamide (50 mg/kg) This is an open-labeled single arm study of Cyclophosphamide (50 mg/kg) administered intravenously IV Cyclophosphamide: Cyclophosphamide (50 mg/kg) intravenously daily for 4 consecutive days (total 200 mg/kg) followed by granulocyte colony-stimulating factor (5 µg/kg/day)

Baseline Measures
   IV Cyclophosphamide (50 mg/kg) 
Overall Participants Analyzed 
[Units: Participants]
 6 
Age 
[Units: Years]
Mean (Full Range)
 39 
 (19 to 60) 
Age 
[Units: Participants]
Count of Participants
 
<=18 years      0   0.0% 
Between 18 and 65 years      6 100.0% 
>=65 years      0   0.0% 
Sex: Female, Male 
[Units: Participants]
Count of Participants
 
Female      2  33.3% 
Male      4  66.7% 
Region of Enrollment [1] 
[Units: Participants]
 
United States   6 
[1] Number of participants
Number of Participants with diagnosis of scleroderma 
[Units: Participants]
 6 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Improvement in the Modified Rodnan Skin Score.   [ Time Frame: 0 to 24 months ]

2.  Secondary:   Change in the HAQ-DI, PGA, FVC and DLCO   [ Time Frame: 0-24 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Gwen Leatherman,R.N.,M.S.
Organization: Johns Hopkins University
phone: 410-550-8582
e-mail: gleathe@jhmi.edu


Publications of Results:

Responsible Party: Fredrick M. Wigley, Johns Hopkins University
ClinicalTrials.gov Identifier: NCT00501995     History of Changes
Other Study ID Numbers: 00-11-17-02
Study First Received: July 13, 2007
Results First Received: March 25, 2014
Last Updated: May 15, 2017